Planning for Scale
New Partnerships, Funding, and Technology Expedite Growth and Impact

Our newest partnership positions SEngine Precision Medicine to rapidly accelerate new drug development and ready new therapies for clinical trial. Coupled with exciting news about the close of our Series A fundraising, key hires and new advances to our 3D organoid technology, I'm pleased to share this update on our progress with you.

Carla Grandori, MD, PhD
CEO & Co-Founder

Series A Closes Amidst Increasing Momentum

This week, we announced that we've closed our Series A. The $5.1MM raised provides us with the resources to advance and scale our diagnostic and drug discovery platform (the PARIS® Test), fuel integration of AI technologies, and accelerate commercialization of personalized oncology. Our most sincere thanks to those who supported us, including Bangarang Group, who led this round. This brings total fundraising to date to more than $9MM. Read more in Business Insider.

Atomwise Partnership Leverages 3D Organoids & AI to Accelerate Drug Development

SEngine's new partnership with Atomwise propels us toward our goals of bringing our first drug candidate to pharma for clinical trial and creating a model for the next generation of drug discovery. Together, we will leverage the convergence of our high-throughput 3D organoid platform and Atomwise's AI technology to identify new targets for trial in a fraction of the time and cost of a traditional clinical trial. Read more in this Fierce Biotech article. 

Photo: SEngine Precision Medicine CBO Ulrich Mueller joins Atomwise panel at BioPharma, part of Biotech Week Boston, in mid-September to announce new partnership. Photo credit: Atomwise

Facility Tour: Update on New Joint Venture in Asia

Efforts to open the new Noble Medical Technology– SEngine's new Joint Venture in China–are progressing well. We recently returned from Shandong Province where we toured the expansive facility that will soon house the new enterprise. Through this joint venture, SEngine will dramatically increase our volume of patient samples, leading to vastly more data to rapidly inform development of new cancer drug targets.

Tom Neary Joins as SEngine's New CFO

Our progress toward commercializing and scaling the PARIS® Test took a huge step forward with the addition of our new Chief Financial Officer, Tom Neary. Tom brings extensive experience in fundraising, mergers and acquisitions, financial operations as well as background working in growing technology companies. Learn more about this new addition in GeekWire.  We welcome Tom and all the new members of our expanding SEngine team.

Increasing Data Drives Advancements in PARIS® Test

As we continue to see significant growth in the rate of new patient samples, we’re leveraging the wealth of data we’ve collected to advance our proprietary diagnostic and drug discovery platform. We’ve recently streamlined The PARIS® Test so we no longer need to interrogate hundreds of drugs for certain cancer types but can instead focus on a subset of drugs–typically about 48–that can be custom selected to match each individual cancer type and genetics. This approach is more likely to be effective for patients, more efficient, and also far more cost effective.

CEO's Closing Thoughts

I bring you this update with great enthusiasm and appreciation for the support that helped us get here and continues to provide the fuel for what's next as we prepare to scale and increase our impact. If you'd like to learn more about what's ahead for us, feel free to email me or find me on LinkedIn

Kind Regards, 

If you haven't already subscribed to receive our newsletters, you can do so here. Click below to share this newsletter with a friend or colleague.

Forward to a Friend
Copyright © 2019 SEngine Precision Medicine, All rights reserved.

Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp